PRQR ProQR Therapeutics N.V.

6.22
-0.08  -1%
Previous Close 6.3
Open 6.39
Price To Book 3.14
Market Cap 242,036,304
Shares 38,912,589
Volume 128,683
Short Ratio
Av. Daily Volume 165,727
Stock charts supplied by TradingView

NewsSee all news

  1. ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA

  2. ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  3. ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

    Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated with a favorable

  4. ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for

  5. ProQR to Present at Two Investor Conferences in October

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 data due 1H 2021. Phase 1/2 data presented October 10, 2019 noted statistically significant improvement in vision.
Sepofarsen
Leber's Congenital Amaurosis (LCA) - Genetic blindness
Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.
QR-010
Cystic Fibrosis
Phase 1/2 interim analysis announced March 26, 2019. Future development to be conducted by Wings Therapeutics.
QR-313
Epidermolysis bullosa
Phase 1/2 trial to be initiated 2H 2019.
QR-1123
autosomal dominant retinitis pigmentosa (adRP)
Phase 1/2 interim data due 1Q 2020.
QR-421a - STELLAR
Usher Syndrome Type 2

Latest News

  1. ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA

  2. ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe

  3. ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

    Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated with a favorable

  4. ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for

  5. ProQR to Present at Two Investor Conferences in October

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the

  6. ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the